

Involvement of visceral adipose tissue in the development of vascular damage in chronic kidney disease



Prof. MARÍA S. FERNÁNDEZ-ALFONSO

Directora Instituto Pluridisciplinar

Grupo GESCAMET

Instituto Pluridisciplinar UCM

Paseo Juan XXIII,

1 - 28040 Madrid, Spain

marisolf@ucm.es

SHORT SUMMARY:

Chronic kidney disease (CKD) is a progressive disorder associated with increased cardiovascular morbidity and mortality. Among the contributing factors to vascular dysfunction in CKD, visceral adipose tissue (VAT) has emerged as a key player due to the link between its pro-inflammatory, pro-fibrotic and pro-osteogenic microenvironment in CKD with both kidney and vascular damage. VAT secretes various adipokines and cytokines, including tumor necrosis factor-alpha (TNF- α), interleukin-1(IL-1), IL-6, and transforming growth factor β (TGF β), associated to oxidative stress, endothelial dysfunction, and arterial stiffness. Moreover, it secretes bone morphogenetic proteins (BMPs) which play a crucial role in vascular remodeling in CKD.

BMP-2, a driver of vascular calcification, is upregulated in VAT associated to inflammation and arterial stiffness. Conversely, BMP-7 exerts protective effects by inhibiting fibrosis and vascular calcification while promoting tissue repair and regeneration. The imbalance between BMP-2 and BMP-7 in CKD contributes to progressive vascular damage, highlighting the need for targeted therapeutic interventions. These effects are further exacerbated in individuals with diabetes, where insulin resistance and hyperglycemia enhance VAT dysfunction, worsening vascular injury and CKD progression. Finerenone, a novel selective nonsteroidal MR antagonist, has shown promising effects restoring the imbalance observed in CKD between the procalcifying BMP-2 and the nephroprotective BMP-7 in plasma, kidney, and VAT in associated with a reduction in inflammation and fibrosis independently from changes in glucose homeostasis.

PROFESSIONAL INTERESTS:

- Pathophysiological mechanisms in cardiovascular disease (CVD) aimed at evaluating new drugs and designing new intervention strategies to prevent and/or slow the progression of CVD,
- Role of perivascular adipose tissue on vascular function and arterial stiffness,
- With a translational perspective, to investigate and foster community pharmacist´s intervention, delivered as a combination of health education, nutritional follow-up, and modification of lifestyle habits, to prevent and/or reduce CVD associated to CV risk factors.

RELEVANT PUBLICATIONS:

1. Sanz-Gómez M, Manzano-Lista FJ, Vega-Martín E, González-Moreno D, Alcalá M, Gil-Ortega M, Somoza B, Pizzamiglio C, Ruilope LM, Aranguez I, Kolkhof P, Kreutz R, Fernández-Alfonso MS. Finerenone protects against progression of kidney and cardiovascular damage in a model of type 1 diabetes through modulation of proinflammatory and osteogenic factors. *Biomedicine & Pharmacotherapy* 168 (2023) 115661.
2. Mancia Chairperson G, Kreutz Co-Chair R, Brunström M, Burnier M, Grassi G, Januszewicz A, Muijesan ML, Tsiofis K, Agabiti-Rosei E, Algharably EAE, Azizi M, Benetos A, Borghi C, Hitij JB, Cifkova R, Coca A, Cornelissen V, Cruickshank K, Cunha PG, Danser AHJ, de Pinho RM, Delles C, Dominiczak AF, Dorobantu M, Doumas M, Fernández-Alfonso MS, Halimi JM, Járai Z, Jelaković B, Jordan J, Kuznetsova T, Laurent S, Lovic D, Lurbe E,

Mahfoud F, Manolis A, Miglinas M, Narkiewicz K, Niiranen T, Palatini P, Parati G, Pathak A, Persu A, Polonia J, Redon J, Sarafidis P, Schmieder R, Spronck B, Stabouli S, Stergiou G, Taddei S, Thomopoulos C, Tomaszewski M, Van de Borne P, Wanner C, Weber T, Williams B, Zhang ZY, Kjeldsen SE; Authors/Task Force Members. 2023 ESH Guidelines for the management of arterial hypertension The Task Force for the management of arterial hypertension of the European Society of Hypertension Endorsed by the European Renal Association (ERA) and the International Society of Hypertension (ISH). *J Hypertens.* 42(1):p 194, 2024.

3. Manzano-Lista FJ, Sanz-Gómez M, González-Moreno D, Vega-Martín E, Gil-Ortega M, Schulz A, Rubio MÁ, Ruiz-Hurtado G, Ruilope LM, Aránguez I, Kreutz R, Fernández-Alfonso MS. Imbalance in Bone Morphogenic Proteins 2 and 7 Is Associated with Renal and Cardiovascular Damage in Chronic Kidney Disease. *Int J Mol Sci.* 2022;24(1):40.
4. González-Blázquez R, Alcalá M, Steckelings UM, Lorenzo MP, Viana M, Boisvert W, Unger T, Fernández-Alfonso M, Ortega MG, Somoza B. AT2R stimulation with C21 prevents arterial stiffening and endothelial dysfunction in the abdominal aorta from mice fed a high-fat diet. *Clin Sci (Lond)* 2021;135(24):2763-2780.
5. González-Blázquez R, Alcalá M, Fernández-Alfonso M, Steckelings UM, Lorenzo MP, Viana M, Boisvert W, Unger T, Ortega MG, Somoza B. C21 preserves endothelial function in the thoracic aorta from DIO mice: role for AT2, Mas and B2 receptors. *Clin Sci (Lond).* 2021;14;135(9):1145-1163.
6. García-Prieto CF, Gil-Ortega M, Plaza A, Manzano-Lista FJ, González-Blázquez R, Alcalá M, Rodríguez-Rodríguez P, Viana M, Aránguez I, Gollasch M, Somoza B, Fernández-Alfonso MS. Caloric restriction induces H₂O₂ formation as a trigger of AMPK-eNOS-NO pathway in obese rats: Role for CAMKII. *Free Radic Biol Med.* 2019 139:35-45.
7. Fernández-Alfonso MS, Somoza B, Tsvetkov D, Kuczmanski A, D, Dashwood MR, Gil-Ortega M. Role of perivascular adipose tissue in health and disease. *Comprehensive Physiol.* 8(1):23-59, 2017.
8. Fernández-Alfonso MS, Gil-Ortega M, Aranguez I, Souza D, Dreifaldt M, Somoza B, Dashwood MR. Role of PVAT in coronary atherosclerosis and vein graft patency: friend or foe? *Br J Pharmacol.* 2017 174(20):3561-3572. doi: 10.1111/bph.13734.
9. Ruiz-Hurtado G, Sarafidis P, Fernández-Alfonso MS, Waeber B, Ruilope LM. Global cardiovascular protection in chronic kidney disease. *Nat Rev Cardiol.* 13(10):603-8, 2016.
10. Gil-Ortega M, Martín-Ramos M, Arribas SM, González MC, Aranguez I, Ruiz-Gayo M, Somoza B, Fernández-Alfonso MS. Arterial stiffness is associated with adipokine

dysregulation in non-hypertensive obese mice. *Vascul Pharmacol.* 2015 S1537-1891(15)00114-7.

11. Gil-Ortega M, García-Prieto Cf, Ruiz-Hurtado G, Steireif C, González MC, Schulz A, Kreutz R, Fernández-Alfonso MS, Arribas S, Somoza B. Genetic Predisposition to Albuminuria Is Associated With Increased Arterial Stiffness: Role Of Elastin. *Br J Pharmacol.* 172(17):4406-18, 2015.
12. Gil-Ortega M, Somoza B, Huang Y, Gollasch M, Fernández-Alfonso MS. Regional differences in perivascular adipose tissue impacting vascular homeostasis. *Trends Endocr Metab.* 26(7):367-75, 2015.
13. Gil-Ortega M, Condezo-Hoyos L, García-Prieto CF, Arribas SM, González MC, Aranguez I, Ruiz-Gayo M, Somoza B, Fernández-Alfonso MS. Imbalance between pro and anti-oxidant mechanisms in perivascular adipose tissue aggravates long-term high-fat diet-derived endothelial dysfunction. *PLoS One.* 23;9:e95312, 2014.
14. Gil-Ortega M, Stucchi P, Guzmán-Ruiz R, Cano V, Arribas S, González MC, Ruiz-Gayo M, Fernández-Alfonso MS, Somoza B. Adaptative Nitric Oxide Overproduction in Perivascular Adipose Tissue during Early Diet-Induced Obesity. *Endocrinology.* 151:3299-3306, 2010.
15. Stucchi P, Cano V, Ruiz-Gayo M, Fernández-Alfonso MS. Aliskiren reduces gain of body weight, adiposity and plasma leptin during diet-induced obesity. *Br J Pharmacol,* 158(3):771-8, 2009.
16. Gálvez-Prieto B, Bolbrinker J, Stucchi P, de las Heras AI, Merino B, Arribas S, Ruiz-Gayo M, Huber M, Wehland M, Kreutz R, Fernandez-Alfonso MS. Comparative expression analysis of the renin-angiotensin system components between white and brown perivascular adipose tissue. *J Endocrinology* 197:1-11, 2008.
17. Gálvez B, de Castro J, Herold D, Dubrovska G, Aranguez I, Luft FC, Gollasch M, M. Ramos P, Fernández-Alfonso MS. Perivascular adipose tissue and mesenteric vascular function in spontaneously hypertensive rats. *Arterioscler Thromb Vasc Biol* 26:1297-302, 2006.
18. Fernandez-Alfonso MS. Regulation of vascular tone: the fat connection. *Hypertension* 44:255-2566, 2004.